Igor Tubin, MD
Cardiovascular Disease · Lafayette, INNPI 1144253170
Payments from drug & device makers
Across 61 payments — averaging $68.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medical Device Business Services, Inc.$1K
- Boston Scientific$475
- Vifor Pharma, Inc.$200
- Medtronic$176
- Biosense Webster, Inc.$167
- plus $9 from 1 others
What the payments were for
- Speaking & faculty fees$2005%
- Travel & lodging$2,38457%
- Food & beverage$1,61338%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $2,009 |
| Medical Device Business Services, Inc. | 4 | $1,160 |
| Boston Scientific | 13 | $475 |
| Vifor Pharma, Inc. | 1 | $200 |
| Medtronic | 4 | $176 |
| Biosense Webster, Inc. | 5 | $167 |
| Elutia, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,342
- Carto 3$1,074
- Veltassa$200
- WATCHMAN Access System$156
- Micra$142
How this compares
$4,197 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 446 | $483,815 |
| EntrestoSacubitril/Valsartan | 157 | $201,052 |
| XareltoRivaroxaban | 144 | $176,329 |
| JardianceEmpagliflozin | 128 | $125,228 |
| FarxigaDapagliflozin Propanediol | 24 | $23,630 |
| Digoxin | 282 | $10,756 |
| Dofetilide | 42 | $9,198 |
| Flecainide Acetate | 194 | $8,034 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $3,226 |
| Metoprolol Succinate | 247 | $2,991 |
| Ezetimibe | 59 | $2,483 |
| Potassium Chloride | 103 | $2,435 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 90 | $2,099 |
| Atorvastatin Calcium | 174 | $1,858 |
| Spironolactone | 198 | $1,819 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lafayette
- Steven SteinhublLafayette$2.4M
- John McGintyRichmond$3.7M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
- Vijay RaoIndianapolis$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.